First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.

被引：0

作者：

Di Giacomo, Anna Maria

Santangelo, Federica

Amato, Giovanni

Simonetti, Elena

Graham, Jill

Lahn, Michael M. F.

Van der Veen, Lars Anders

Johnson, Zoe

Pickering, Catherine Anne

Durini, Marco

Tan, Ziyang

Tadepally, Lakshmikanth

Brodin, Petter

Occhipinti, Mariaelena

Simonelli, Matteo

Carlo-Stella, Carmelo

Santoro, Armando

Spiliopoulou, Pavlina

Evans, T. R. Jeffry

Maio, Michele

机构：

[1] Univ Hosp Siena, Ctr Immuno Oncol, Siena, Italy

[2] Azienda Osped Univ Senese, UOC Immunoterapia Oncol, Siena, Italy

[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[4] iOnctura SA, Geneva, Switzerland

[5] Covance Clin & Peri Approval Serv LTD, Milan, Italy

[6] Karolinska Inst, Stockholm, Sweden

[7] Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden

[8] Radiomics, Liege, Belgium

[9] Humanitas Canc Ctr, Milan, Italy

[10] IRCSS Humanitas Res Hosp, Milan, Italy

[11] Humanitas Univ, IRCCS Humanitas Res Hosp, Dept Biomed Sci, Milan, Italy

[12] Princess Margaret Canc Ctr, Toronto, ON, Canada

[13] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3107

引用

页数：1

共 50 条

[1] First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma
Di Giacomo, A. M.
Santangelo, F.
Amato, G.
Simonetti, E.
Graham, J.
Lahn, M.
Zorilla, R.
van der Veen, L.
Johnson, Z.
Pickering, C.
Marechal, E.
Blanco, J.
Blanco, J.
Durini, M.
Gufford, B.
Lakshmikanth, T.
Brodin, P.
Spiliopoulou, P.
Evans, T. R. J.
Maio, M.
ANNALS OF ONCOLOGY, 2021, 32 : S1438 - S1438
[2] Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Di Giacomo, A. M.
Simonelli, M.
Santangelo, F.
Amato, G.
Simonetti, E.
Graham, J.
Lahn, M.
Di Conza, G.
Hammett, T.
Zorrilla, R.
Kaur, P.
Ziyang, T.
Lakshmikanth, T.
Brodin, P.
Occhipinti, M.
Carlo-Stella, C.
Santoro, A.
Spiliopoulou, P.
Evans, T. R. J.
Maio, M.
ANNALS OF ONCOLOGY, 2024, 35 : S500 - S500
[3] First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).
Di Giacomo, Anna Maria
Santangelo, Federica
Amato, Giovanni
Simonetti, Elena
Graham, Jill
Lahn, Michael M. F.
Di Conza, Giusy
Hammett, Tracey
Zorrilla, Rebeca
Durini, Marco
Tan, Ziyang
Tadepally, Lakshmikanth
Brodin, Petter
Occhipinti, Mariaelena
Simonelli, Matteo
Carlo-Stella, Carmelo
Santoro, Armando
Spiliopoulou, Pavlina
Evans, T. R. Jeffry
Maio, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors
Omlin, Aurelius Gabriel
Spicer, James F.
Sarker, Debashis
Pinato, David James
Agarwal, Roshan
Cassier, Philippe Alexandre
Stavraka, Chara
Blanco, Monsterrat
Suder, Aneta
Allan, Suzanne
Heaton, Simon
Decordova, Shaun
Pope, Lorna
Prince, Jenny
Noguchi, Kohei
Jones, Keith
Inatani, Michiyasu
Shiokawa, Rie
Banerji, Udai
Blagden, Sarah Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[5] A first-in-human phase I study of CYH33, a phosphatidylinositol 3-kinase (PI3K) α selective inhibitor, in patients with advanced solid tumors.
Wei, Xiao-Li
Xu, Rui-hua
Zhao, Hongyun
Zhang, Yang
Zou, Ben-Yan
Wang, Feng
Liu, Jihong
Wang, Zhiqiang
Qiu, Miao-Zhen
Yu, Qiuqiong
Liu, Yun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors
Schwertschlag, U. S.
Chiorean, E. G.
Anthony, S. P.
Sweeney, C. J.
Borad, M. J.
Von Hoff, D. D.
Garlich, J. R.
Shelton, C. F.
Ramanathan, R. K.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[7] IOA-244 IS A NON-ATP-COMPETITIVE, HIGHLY SELECTIVE, TOLERABLE PHOSPHOINOSITIDE 3-KINASE DELTA INHIBITOR THAT DIRECTLY TARGETS SOLID TUMOURS AND BREAKS IMMUNE TOLERANCE
Di Conza, Giusy
Van der Veen, Lars
Tarantelli, Chiara
Bertoni, Francesco
Fraser, Amy
Shah, Pritom
Tiede, Simon
Tesmer, Laura
Hummer, Gerhard
Vadas, Oscar
Lahn, Michael
Tyzoonn, Nomanbhoy
Johnson, Zoe
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A926 - A926
[8] Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Ky) inhibitor
Knoerzer, Deborah
Teresk, Martin
Krutzik, Peter
O'Donnell, Erika
DeCrescenzo, Gary
Welsch, Dean
Emery, Caroline
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[9] IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance Check for updates
Johnson, Zoe
Tarantelli, Chiara
Civanelli, Elisa
Cascione, Luciano
Spriano, Filippo
Fraser, Amy
Shah, Pritom
Nomanbhoy, Tyzoon
Napoli, Sara
Rinaldi, Andrea
Niewola-Staszkowska, Karolina
Lahn, Michael
Perrin, Dominique
Wenes, Mathias
Migliorini, Denis
Bertoni, Francesco
van der Veen, Lars
Di Conza, Giusy
CANCER RESEARCH COMMUNICATIONS, 2023, 3 (04): : 576 - 591
[10] ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors
Rasco, Drew
Lakhani, Nehal
Sullivan, Ryan
Mita, Monica
Shah, Jaimini
Usansky, Helen
Reddy, Sanjeeva
Rao, Niranjan S.
Toker, Sarper
Denis, Louis
Flaherty, Keith
Tolcher, Anthony
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →